Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use
SI Gavrilova, A Alvarez - Medicinal Research Reviews, 2021 - Wiley Online Library
Alzheimer's disease (AD) is the most common neurocognitive disorder and a global health
problem. The prevalence of AD is growing dramatically, especially in low‐and middle …
problem. The prevalence of AD is growing dramatically, especially in low‐and middle …
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use.
SI Gavrilova, A Alvarez - Medicinal Research Reviews, 2020 - europepmc.org
Alzheimer's disease (AD) is the most common neurocognitive disorder and a global health
problem. The prevalence of AD is growing dramatically, especially in low-and middle …
problem. The prevalence of AD is growing dramatically, especially in low-and middle …
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use
SI Gavrilova, A Alvarez - Medicinal Research Reviews, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Alzheimer's disease (AD) is the most common
neurocognitive disorder and a global health problem. The prevalence of AD is growing …
neurocognitive disorder and a global health problem. The prevalence of AD is growing …
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use
SI Gavrilova, A Alvarez - Medicinal research reviews, 2021 - pubmed.ncbi.nlm.nih.gov
Alzheimer's disease (AD) is the most common neurocognitive disorder and a global health
problem. The prevalence of AD is growing dramatically, especially in low-and middle …
problem. The prevalence of AD is growing dramatically, especially in low-and middle …
[引用][C] Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use
SI Gavrilova, A Alvarez - Medicinal Research Reviews, 2020 - elibrary.ru
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use.
SI Gavrilova, A Alvarez - Medicinal Research Reviews, 2021 - search.ebscohost.com
Alzheimer's disease (AD) is the most common neurocognitive disorder and a global health
problem. The prevalence of AD is growing dramatically, especially in low‐and middle …
problem. The prevalence of AD is growing dramatically, especially in low‐and middle …